The PharmaLogic Spotlight reports that through the first half of 2026 the FDA has approved 23 new drugs and two gene/cell therapies, with early use of several agents, and anticipation for CagriSema, a weekly obesity/diabetes treatment, highlighting a shift toward targeted biologics and biosimilars that has moderated costs in inflammatory therapies. A Finnish study found 150 APIs exited the national reimbursement system between 2010 and 2022, with about half used short-term and half long-term; while 62% of these APIs remained on the market without reimbursement, the remaining 38% were withdrawn, and remaining APIs tended to be older and cheaper. In Pennsylvania, the state budget includes PBM reforms requiring networks to let pharmacies reapply after 12 months if in good standing, a move supporters say will aid several dozen pharmacies facing network restrictions. The PBM reform comes amid ongoing scrutiny of the role of PBMs, which negotiate reimbursement rates and control access to networks; supporters like Rob Frankil argue the measure helps pharmacies in need. The policy is framed as progress in addressing access while acknowledging that broader PBM issues remain, including reimbursement levels and network dynamics. Overall, the developments reflect a broader shift in drug approvals, reimbursement lifecycles, and payer–pharmacist relationships shaping access and costs.